linjc16/ctgov huggingface dataset:
A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if L-756423, an anti-HIV drug, is safe to give with indinavir and if it works well at lowering the level of HIV in the blood (viral load).

Detailed Description
-----------------
All patients receive L-756423 plus indinavir plus two licensed nucleoside reverse transcriptase inhibitors (NRTIs), at least one to which the patient is naive. Patients remain on the drug regimen for 12 weeks (with possible extension to 16 weeks). Patients are evaluated with physical examinations and laboratory tests for blood and urine at Weeks 1, 2, 4, 6, 8, and 12 and two weeks post study. Plasma viral RNA is measured at Weeks 1, 2, 4, 6, 8, and 12. CD4 cell counts are measured at Weeks 2,4,8, and 12.

Official Title
-----------------
A Multicenter, Open-Label, Pilot Study to Evaluate the Safety and Activity of L-756423/Indinavir Sulfate, 800/400 Mg b.i.d. in Combination With Two nRTIs in HIV-Infected Patients Who Failed an Indinavir Containing Regimen

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: L-756423
* Drug: Indinavir sulfate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria You may be eligible for this study if you: Are HIV-positive. Are at least 18 years old. Have a viral load of at least 1,000 copies/ml. Have a CD4 cell count of at least 100 cells/mm3. Have experienced treatment failure (your viral load increased significantly) within 24 weeks of study entry while taking indinavir. Exclusion Criteria You will not be eligible for this study if you: Are taking nonnucleoside reverse transcriptase inhibitors (NNRTIs).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: L-756423|nan|
|Drug: Indinavir sulfate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Therapy, Combination, HIV Protease Inhibitors, Indinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load
Estimation of Disability Adjusted Life Years in Reunion Island and Comparison to Metropolitan France and Other Countries in the Indian Ocean Zone

Study Overview
=================
Brief Summary
-----------------
AVIRON study aims at estimating the burden of various causes of death and morbidity in the Reunion Island population.

Detailed Description
-----------------
The identification of health priorities on a given territory is a major field of the research in Public health. The World Health Organization leads since the 1990s the Global Burden of Disease study. This study has for objective to estimate the burden of various causes of death and morbidity in a given population. It defines a standardized measure allowing the comparisons between the various countries. The measure developed internationally is the Disability-adjusted life year (DALY). For the Indian Ocean zone, the international study provides values of DALYs for Madagascar, Seychelles and Mauritius. The estimation of DALYs for Reunion Island are based on data of mainland France and does not take into account specificities from Reunion Island. To better define Public health priorities, it seems essential to decline this measure at the regional level.

Official Title
-----------------
Estimation Des années de Vie ajustées Sur l'incapacité à La réunion et Comparaison à la France métropolitaine et Aux Pays de la Zone Océan Indien

Conditions
-----------------
Quality-Adjusted Life Years, Epidemiology, Public Health

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The whole population of Reunion Island Exclusion Criteria: People not living in Reunion Island
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of years of life lost or lived with disabilities |  | 3 years | 
| Prevalence of years of life lost or lived with disabilities |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Disability-Adjusted Life Years, Epidemiology, Public Health
Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome.

Study Overview
=================
Brief Summary
-----------------
Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy. As a result, patients have a markedly increased risk of developing ischemic stroke, small-fiber peripheral neuropathy, cardiac dysfunction and chronic kidney disease. Because this disease is a rare disease most of the time it is misdiagnosed, so in this study we will check out the Prevalence of lysosomal hydrolase alpha-glagtosidase deficiency ( Fabry disease) in patients with Antiphospholipid Syndrome.

Detailed Description
-----------------
the investigators would like to assess the prevalence of Fabry in men and women aged 18-100 who were diagnosed with antiphospholipid syndrome in our departmental clinic in 2000-2017 It is very important to diagnose Fabri that then the treatment of patients can vary dramatically. The study will include 100 adult patients (18-100) men and women. Testing for the Fabri test in men is an enzyme test and will be performed subject to their consent to sign informed consent. In the women, an enzyme test will be carried out, and the plasma Lys-3-3 plasma storage, as recommended in the recently published diagnostic algorithms, is examined. If diagnosed, a patient will be referred to a genetic institute for further genetic counseling

Official Title
-----------------
Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients

Conditions
-----------------
Antiphospholipid Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: antiphospholipid syndrome


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Antiphospholipid syndrome. able to read and sign inform concent Exclusion Criteria: • Fabry disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: antiphospholipid syndrome<br>blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease | Diagnostic Test: antiphospholipid syndrome<br>* blood test for enzyme test,plasma and Lys-3-3 plasma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lys-3-3 plasma | blood test to find the enzyme for Fabry's disease | an average of 1 year |
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis (HD) patients. In the present study, we assess whether low-dose spironolactone treatment reduces the high incidence of cardio- and cerebrovascular (CCV) morbidity and mortality in HD patients. The investigators' hypothesis is that aldosterone receptor blockade by spironolactone reduces the risk of both CCV morbidity and death among HD patients.

Conditions
-----------------
End-stage Renal Failure

Intervention / Treatment
-----------------
* Drug: Spironolactone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemodialysis patients undergoing 4-hour-long HD thrice a week for at least 2 years With an average serum potassium level (immediately before dialysis on the first day of the week) of <6.5 mEq/l over the previous 2 months With a 24-hour urine output of <500 ml Exclusion Criteria: A history of noncompliance Unstable vascular access Hypotension Hepatic failure Active cancer Any life-threatening disease other than ESRD

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: spironolactone<br> | Drug: Spironolactone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardio- and cerebrovascular events |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death from all causes |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemodialysis, cardiovascular event, spironolactone
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Study Overview
=================
Brief Summary
-----------------
Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled study.

Detailed Description
-----------------
This is a Phase 2 open-label, single-treatment group, baseline-controlled study designed to verify product safety, gather data on the percentage of subjects with pituitary tumors with increased uptake of FolateScan in tumors and correlate the immunohistochemical staining findings with the FolateScan images, in subjects with pituitary tumors.

Official Title
-----------------
A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Conditions
-----------------
Pituitary Tumors

Intervention / Treatment
-----------------
* Drug: Technetium Tc 99m EC20


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must meet the following eligibility requirements to be enrolled in the study: Subject must be 18 years of age or older. Subject must have a pituitary tumor. Subject must have good kidney function. 3. Subject must provide written informed consent prior to enrollment. Exclusion Criteria: Subjects must be excluded if any of the following conditions are present: Subject is pregnant or breastfeeding. Subject is simultaneously participating in another investigational drug study. Subject has completed the follow-up phase of any previous study loess than 30 days prior to enrollment in this study. Subject is unable to tolerate conditions for radionuclide imaging. Subject has been administered another radiopharmaceutical that would interfere with the assessment of Technetium Tc 99m EC20.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Technetium Tc 99m EC20<br> | Drug: Technetium Tc 99m EC20<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pituitary Tumors
Investigating the Physiology of Targeted Theta-burst Neuromodulation

Study Overview
=================
Brief Summary
-----------------
This research seeks to study the physiological effects of theta-burst transcranial magnetic stimulation (TMS) in the brains of healthy controls using functional MRI and spectroscopy.

Official Title
-----------------
Investigating the Physiology of Targeted Theta-burst Neuromodulation

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Device: theta-burst TMS
* Device: sham theta-burst TMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No personal history of neurological or psychiatric disorders Exclusion Criteria: Have had a brain injury or neurological disorder Have ever suffered an epileptic fit Have any non-removable metal implants Drink more than 20 units of alcohol per week on a regular basis Currently take any illicit drugs on regular basis Likely to be pregnant Ever suffered from a serious mental illness such as schizophrenia, severe depression or bipolar disorder Currently take any psychotropic medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: theta-burst TMS<br>Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging) | Device: theta-burst TMS<br>* This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.<br>|
| Sham Comparator: sham theta-burst TMS<br>Sham protocol for theta-burst transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging) | Device: sham theta-burst TMS<br>* This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in functional connectivity following TMS administration using functional MRI | Changes in brain connectivity will be assessed by comparing functional MRI scans after theta-burst TMS and sham theta-burst TMS | One hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in brain metabolites following TMS administration using MR spectroscopy | Using MRI scans, changes in metabolites in the brain will be assessed following theta-burst TMS and sham TMS | One hour |
Etiological Factors, Risk Factors and Early Stages of Chronic Disease in Different Degrees of Childhood Overweight

Study Overview
=================
Brief Summary
-----------------
Children and adolescents with overweight and obesity are predisposed to significant health problems. It is known that childhood obesity can adversely affect almost every organ system, and if left untreated, the major impact of childhood overweight is likely to be felt in the next generation of adults. The aim of  Kijk op overgewicht bij kinderen is to collect and follow-up longitudinal data from a population of different degrees of children with overweight regarding etiological factors, risk factors and early stages of chronic disease in different degrees of childhood overweight.

Detailed Description
-----------------
Furthermore, from april 2020 onwards, a prospective sub study will be conducted. This sub study aims to investigate the changes in lifestyle behaviour of children with overweight or obesity and their families during the COVID-19 pandemic, including the (governmental) measures taken for this, and the effect of obesity and different weight-related risk factors on the host response of these children. The goal of this sub study is to collect data to enable analyses for future research questions regarding the influence of the COVID-19 on the lifestyle of a child with overweight and their family. Endpoints are for example physical activity, eating behavior, BMI-z score, remote lifestyle coaching, quality of life and parental practices regarding nutrition and physical activity behavior. We will also measure symptoms associated with COVID-19 and the host response that target COVID-19.

Official Title
-----------------
Kijk op Overgewicht Bij Kinderen: Study Regarding Etiological Factors, Risk Factors and Early Stages of Chronic Disease in Different Degrees of Childhood Overweight

Conditions
-----------------
Childhood Obesity

Intervention / Treatment
-----------------
* Other: Lifestyle intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in the COACH program Aged till 18 years old (at time of inclusion) Overweight or obesity according to International Obesity Task Force (IOTF) criteria Exclusion Criteria: • None

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lifestyle intervention<br>lifestyle intervention | Other: Lifestyle intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of overweight or obese children |  | approximately 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
overweight, obesity, children, lifestyle intervention
Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia

Study Overview
=================
Brief Summary
-----------------
Nowadays, multiple treatment modalities have been applied clinically to treat androgenic alopecia, such as Follicular unit transplantation(FUT), finasteride, platelet-rich plasma injection(PRP), etc. In this clinical trial, the investigators aim to analyze the effect of nanofat grafting on treating androgenic alopecia in male.

Detailed Description
-----------------
The investigators will treat the hair loss area of a patient by processed nanofat grafting. The participants were asked to come back 1、3、6、9、12 months after treatment for further follow-up. Before and after the treatment, the hair and follicular will be assessed subjectively by satisfaction assessment, dermatoscope.

Official Title
-----------------
Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia

Conditions
-----------------
Androgenic Alopecia

Intervention / Treatment
-----------------
* Procedure: Nanofat grafting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male patients with androgenic alopecia aging from 18 to 50. No scars and wounds on the alopecia area. No skin disease or serious cardiovascular disease. Preoperative examinations remain healthy. Exclusion Criteria: Serious chronic heart, liver, kidney, blood system disease Allergic diseases, skin inflammation or wounds Alopecia but not androgenic alopecia Acute or chronic infection Take anticoagulant drugs Active vitiligo, psoriasis, systemic lupus erythematosus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: processed Nanofat grafting<br>processed autologous Nanofat will be injected into the area of the scalp with androgenic alopecia. | Procedure: Nanofat grafting<br>* hair loss area will be treated by processed autologous Nanofat grafting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dermatoscope | the density of hair follicle and diameter of hair will be analized by dermatoscope before and after the treatment of Nanofat grafting. | Baseline and at1,3,6,9,12 months after the treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nanofat, hair loss, prp